Health Canada has given VeraLight the go-ahead to commercialize Scout, a less-invasive device that uses light to quickly detect pre-diabetes or type 2 diabetes. The company is awaiting marketing approval in the European Union and hopes to secure about $15 million to seek FDA approval for the device.

Related Summaries